Back to top
more

BioHarvest Sciences Inc. (BHST)

(Delayed Data from NSDQ)

$7.69 USD

7.69
115

+0.09 (1.16%)

Updated Aug 1, 2025 03:43 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value A Growth F Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 42% (143 out of 246)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

BioHarvest Sciences Inc. (BHST) Surges 5.6%: Is This an Indication of Further Gains?

by Zacks Equity Research

BioHarvest Sciences Inc. (BHST) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

Zacks Equity Research

What Makes BioHarvest Sciences Inc. (BHST) a Good Fit for 'Trend Investing'

by Zacks Equity Research

BioHarvest Sciences Inc. (BHST) could be a great choice for investors looking to make a profit from fundamentally strong stocks that are currently on the move. It is one of the several stocks that made it through our "Recent Price Strength" screen.

Zacks Equity Research

BioHarvest Sciences Inc. (BHST) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research

BioHarvest Sciences Inc. (BHST) delivered earnings and revenue surprises of 13.33% and 1.42%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Adherex Technologies Inc. (FENC) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research

Adherex Technologies (FENC) delivered earnings and revenue surprises of 66.67% and 9.32%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

BioHarvest Sciences Inc. (BHST) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

by Zacks Equity Research

BioHarvest Sciences Inc. (BHST) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

Entrada Therapeutics, Inc. (TRDA) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research

Entrada Therapeutics (TRDA) delivered earnings and revenue surprises of 46.15% and 111.61%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Adma Biologics (ADMA) Misses Q1 Earnings and Revenue Estimates

by Zacks Equity Research

Adma Biologics (ADMA) delivered earnings and revenue surprises of -12.50% and 3.61%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Ginkgo Bioworks Holdings, Inc. (DNA) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research

Ginkgo Bioworks (DNA) delivered earnings and revenue surprises of -28.46% and 17.12%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

BioHarvest Sciences Inc. (BHST) Soars 5.2%: Is Further Upside Left in the Stock?

by Zacks Equity Research

BioHarvest Sciences Inc. (BHST) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

Zacks Equity Research

Kymera Therapeutics (KYMR) Moves 13.8% Higher: Will This Strength Last?

by Zacks Equity Research

Kymera Therapeutics (KYMR) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

Zacks Equity Research

BioHarvest Sciences Inc. (BHST) Reports Q4 Loss, Lags Revenue Estimates

by Zacks Equity Research

BioHarvest Sciences Inc. (BHST) delivered earnings and revenue surprises of -41.67% and 1.05%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Precision BioSciences (DTIL) Reports Q4 Loss, Misses Revenue Estimates

by Zacks Equity Research

Precision BioSciences (DTIL) delivered earnings and revenue surprises of -661.90% and 93.28%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Strength Seen in BioHarvest Sciences Inc. (BHST): Can Its 12.7% Jump Turn into More Strength?

by Zacks Equity Research

BioHarvest Sciences Inc. (BHST) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

Zacks Equity Research

BioHarvest Sciences Inc. (BHST) Reports Q3 Loss, Misses Revenue Estimates

by Zacks Equity Research

BioHarvest Sciences Inc. (BHST) delivered earnings and revenue surprises of -220% and 2.26%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?